Rhinoconjunctivitis Clinical Trial
Official title:
A Motivation-enhancing Intervention to Retain Participants in a Trial After Treatment With Allergen Immunotherapy
The motivation-enhancing intervention is designed for participants in the ILIT.NU trial. The participants are patients with hay fever who are treated with a vaccination in an inguinal lymph node. The motivation-enhancing intervention is a web-based app developed in collaboration with patient partners and is intended to increase retention and reporting in the ILIT.NU trial.
The ILIT.NU trial (EudraCT 2020-001060-28) investigates whether patient reported outcome measures compound symptom-medication score (cSMS) are relieved by intralymphatic immunotherapy (ILIT). The participants are asked for a three-year period to attend annual consultations and to daily fill in an online questionnaire about their allergy symptoms and medication use during the grass pollen season (100 days). High attrition rates have been a problem in previous ILIT trials. High attrition affects generalizability, validity and reliability of a trial. To increase retention and reporting in the ILIT.NU trial, a motivation-enhancing web-based app has been developed. The web app is based on the Self-Determination Theory and is developed in collaboration with patient partners and clinicians. Participants are randomized across treatment group to either the motivation-enhancing web app or the standard reporting method. The project is conducted as a Study Within a Trial (SWAT). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02849210 -
A Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea
|
Phase 1 | |
| Completed |
NCT02150343 -
Phase II HDM-SPIRE Safety and Efficacy Study
|
Phase 2 | |
| Completed |
NCT02340130 -
Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma
|
Phase 2 | |
| Completed |
NCT01923792 -
ToleroMune House Dust Mite Follow on Study
|
N/A | |
| Completed |
NCT01949441 -
ToleroMune House Dust Mite (HDM) Tolerability Study
|
Phase 2 | |
| Completed |
NCT01949428 -
House Dust Mite Observational Study
|
N/A | |
| Completed |
NCT01949415 -
An Optional Investigation of Biomarkers of Efficacy
|
N/A | |
| Completed |
NCT01447784 -
ToleroMune House Dust Mites (HDM) Exposure Chamber Study
|
Phase 2 | |
| Recruiting |
NCT04435990 -
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
|
Phase 3 | |
| Active, not recruiting |
NCT05960266 -
Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study
|
Early Phase 1 | |
| Completed |
NCT01620762 -
Phase III Cat-PAD Study
|
Phase 3 | |
| Completed |
NCT01720251 -
Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy
|
Phase 2 | |
| Completed |
NCT01448603 -
ToleroMune Ragweed Follow up Study
|
N/A | |
| Completed |
NCT01353755 -
2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
|
Phase 3 | |
| Completed |
NCT00574210 -
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
|
Phase 2 | |
| Completed |
NCT00537342 -
Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT)
|
Phase 3 | |
| Completed |
NCT00540631 -
Multicenter Trial of Immunotherapy With House Dust Mite Allergoid
|
Phase 3 | |
| Completed |
NCT05540717 -
Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen
|
Phase 3 | |
| Completed |
NCT02844842 -
Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice
|
||
| Completed |
NCT01734265 -
Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).
|
Phase 2 |